Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from anti-TNF therapy to optimized thiopurines in adults with inflammatory bowel disease
NL-OMON38980Withdrawn
- Sponsor
- Martini Ziekenhuis
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab and adalimumab in inflammatory bowel disease (IBD) and Crohn's disease, sponsored by Martini Ziekenhuis. Planned start Apr 2014; status: withdrawn.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's disease
Beyond the preview
Go deeper on NL-OMON38980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38980.